TICKERNERD
Menu
RGENRGENHealthcare · Medical Instruments & Supplies

RGEN Stock Forecast: Repligen Corp. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$179
−0.72% on the day

The 22 Wall Street analysts covering Repligen Corp. hold a median 12-month price target of $200 — +11.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 22 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$11.3B
Ticker Nerd rank
93/ 100
Median analyst target
$200
Analysts covering
22
Revenue$204.1M+11.9% y/y
Operating income$19.0M
Net income$5.0M
Free cash flow$26.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.0%
1M
−4.3%
YTD
+9.1%
1Y
+13.5%
From 52W high
−8.2%
From 52W low
+73.7%
$103
$195
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Repligen Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
93/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
89
Momentum
86
Quality
83
Growth
80
Value
72
Volatility
72
Accruals
65
Issuance
57
Size
14

Revisions (89): Analysts have, on balance, been raising their forecasts.

Issuance (57): The company has been issuing shares or taking on financing, diluting existing holders.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250Jan 26Apr 26Jul 26Oct 26RGENHigh $235Median $200Low $160

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
18 Buy4 Hold0 Sell
Low $160Median $200High $235

The green dot is the last close — the median target sits +11.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
19 Oct 2026Canaccord GenuityMaintainsHold$145 → $180
7 Oct 2026BarclaysMaintainsOverweight$175 → $225
7 Oct 2026BarclaysMaintainsOverweight—
9 Sept 2026UBSMaintainsBuy$195 → $225
9 Sept 2026UBSMaintainsBuy—
30 July 2026Wells FargoMaintainsOverweight—
30 July 2026Wells FargoMaintainsOverweight$180 → $185
29 July 2026JP MorganMaintainsOverweight—
29 July 2026JP MorganMaintainsOverweight$165 → $175
7 July 2026BenchmarkUpgradeBuy$185
7 July 2026BenchmarkUpgradeBuy—
6 July 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$150 → $160
3 June 2026HSBCMaintainsBuy—
2 June 2026Wolfe ResearchAssumesOutperform$145
15 May 2026RBC CapitalReinstatesOutperform$160
6 May 2026BarclaysMaintainsOverweight—
6 May 2026JP MorganMaintainsOverweight—
20 Apr 2026Canaccord GenuityMaintainsHold—
17 Apr 2026Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

RGEN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

RGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Repligen Corp. returned +13.5% against +15.6% for the S&P 500, dividends included.

RGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120130Jan 26Apr 26Jul 26Oct 26RGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.1%
Analysts raising
1
Analysts cutting
3
Fundamentals

Repligen Corp. (RGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
243.3×

Cheaper than 3% of US stocks

Price / sales
14.4×

Cheaper than 10% of US stocks

Price / book
4.7×

Cheaper than 20% of US stocks

EV / EBITDA
69.2×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
11.9%

Higher than 57% of US stocks

Earnings growth (YoY)
−66.3%

Higher than 7% of US stocks

Gross margin
53.9%

Higher than 66% of US stocks

Operating margin
9.3%

Higher than 63% of US stocks

Net margin
5.3%

Higher than 61% of US stocks

Returns & dividend
Return on equity
2.0%

Higher than 47% of US stocks

Return on assets
1.4%

Higher than 54% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Repligen Corp. (RGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Repligen Corp. has a market value of $11.3B and an enterprise value of $10.0B.

  • Revenue in the twelve months to 30 June 2026: $785.1M. The latest quarter grew 11.9% year on year.

  • Net income over the same four quarters: $41.5M, a 5.3% net margin.

  • Diluted earnings per share, trailing twelve months: $0.73.

  • Free cash flow in the twelve months to 30 June 2026: $110.2M, after $1.8M of capital spending.

  • Shares outstanding: 56.4M.

  • Trailing P/E: 243.3×; forward P/E: 65.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Repligen Corp. employs 2,000 people — $393K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 23 Oct 2026

Data provided by Twelve Data

Peers

RGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
RGENRepligen Corp.$11.3B93
ALGNAlign Technology, Inc.$11.2B86
AVTRAvantor, Inc.$11.7B86
COOThe Cooper Cos., Inc.$12.1B70
BAXBaxter International, Inc.$13.2B93
SOLVSolventum Corp.$15.2B93
ATRAptarGroup, Inc.$8.4B45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Repligen Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RGEN news & analysis

Repligen: A Buy As Its Growth Engine Gears Up

Seeking Alpha · 15 Oct 2026positive

Seeking Alpha reports that Repligen posted 13% organic growth despite Filtration headwinds, supported by momentum in Proteins and Process Analytics. The article says the BioLife acquisition is expected to add cell therapy consumables, synergies and accretive EPS contributions after closing.

Why it matters — RGEN watchers may note the report’s view that Filtration growth could recover and that BioLife may contribute to future growth and earnings.

Repligen to Report Third Quarter 2026 Financial Results

GlobeNewsWire · 13 Oct 2026neutral

Repligen announced it will report its third-quarter 2026 financial results on Tuesday, October 27, 2026.

Why it matters — RGEN watchers can note the scheduled date for the company’s third-quarter results.

Repligen Completes Acquisition of BioLife Solutions

GlobeNewsWire · 6 Oct 2026positive

Repligen completed its previously announced acquisition of BioLife Solutions. BioLife stockholders received $11.25 per share in cash and 0.1442 Repligen shares, with cash paid for fractional shares.

Why it matters — The acquisition adds BioLife’s cell-processing products and customer relationships to Repligen’s cell therapy offering; Repligen said it plans to discuss the transaction’s expected impact on its 2026 financial outlook during its third-quarter earnings call.

BioLife Solutions Shareholders Approve Repligen Merger Agreement

MarketBeat · 5 Oct 2026positive

BioLife Solutions stockholders approved the company's merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026. This clears a key shareholder-vote requirement for the proposed transaction.

Why it matters — The shareholder approval clears a key hurdle toward closing Repligen's proposed merger with BioLife Solutions.

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Business Wire · 10 Sept 2026neutral

Law firm Kahn Swick & Foti, LLC announced it is investigating the proposed sale of BioLife Solutions, Inc. to Repligen Corporation, under which BioLife shareholders would receive $11.25 in cash and 0.1442 shares of Repligen common stock per share. The firm is seeking to determine the adequacy of the price and process in the proposed transaction.

Why it matters — This matters for RGEN watchers because a shareholder investigation could affect the timeline or terms of Repligen's proposed acquisition of BioLife Solutions.

FAQ

Frequently asked questions about RGEN stock

What is the RGEN stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Repligen Corp. have a median 12-month price target of $200, with estimates ranging from $160 to $235. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RGEN stock a buy right now?

Of the 22 analysts covering Repligen Corp., 18 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Repligen Corp. 93 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RGEN?

As at 22 Oct 2026, Repligen Corp. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (89 of 100).

Will RGEN stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +11.9% from the last close, and Ticker Nerd's factor model ranks Repligen Corp. 93 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RGEN stock forecast for 2030?

No analyst covering Repligen Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $160 to $235 over the next 12 months.

How has RGEN stock performed over the past year?

Repligen Corp. returned +13.5% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Repligen Corp. do?

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biologic drugs. Repligen Corporation’s portfolio supports both upstream and downstream workflows across filtration, fluid management, chromatography, process analytics, and single-use technologies.

What is the latest news on RGEN?

The most recent item we track (Seeking Alpha, 15 Oct 2026): "Repligen: A Buy As Its Growth Engine Gears Up". Seeking Alpha reports that Repligen posted 13% organic growth despite Filtration headwinds, supported by momentum in Proteins and Process Analytics. The article says the BioLife acquisition is expected to add cell therapy consumables, synergies and accretive EPS contributions after closing.

Company

About Repligen Corp.

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biologic drugs. Repligen Corporation’s portfolio supports both upstream and downstream workflows across filtration, fluid management, chromatography, process analytics, and single-use technologies. Its products are used by biopharmaceutical companies and contract development and manufacturing organizations to improve efficiency, control, and consistency in production processes. The company offers consumables and instruments such as Protein A ligands, chromatography columns, filtration systems, and analytical tools designed for biologics processing. Headquartered in Waltham, Massachusetts, Repligen Corporation serves customers across North America, Europe, the Asia Pacific, and other international markets, making it an important supplier within the bioprocessing and life sciences tools sector.

CEO Mr. Olivier Loeillot · 2,000 employees · United States · https://www.repligen.com